Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
The Effect of Vitamin D treatment on COVID 19- Patients, an Inverted Propensity Score Weighting (IPSW), and Inverted Probability of Treatment Weighting (IPTW) Analyzed Study
Wadi Al Ramahi et al., The International Arabic Journal of Antimicrobial Agents, doi:10.3823/862
Wadi Al Ramahi et al., The Effect of Vitamin D treatment on COVID 19- Patients, an Inverted Propensity Score Weighting (IPSW), and.., The International Arabic Journal of Antimicrobial Agents, doi:10.3823/862
Mar 2022   Source   PDF  
  All Studies   Meta
Retrospective study comparing 847 patients receiving ≤149,000IU vitamin D and 170 receiving ≥150,000IU, showing no significant differences, however the result may not be very meaningful - membership in the higher cumulative dose group requires longer hospitalization, e.g., patients discharged shortly after admission (a positive outcome) could not be in the higher cumulative dose group.
Wadi Al Ramahi et al., 7 Mar 2022, peer-reviewed, 15 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: iMedPub Journals The International Arabic Journal of Antimicrobial Agents ISSN: 2174-9094 2022 Vol. 12 No. 1:2 doi: 10.3823/862 The effect of vitamin D Treatment on COVID 19patients, an inverted propensity score weighting (IPSW), and inverted probability of treatment weighting (IPTW) analyzed study Jamal Wadi Al Ramahi1, Nour Hasan2, Ammal Matar2, Ma'en Maher Al-Ali3, Lara Abdulhadi2, Dania Abu Kaf3, Waseem Saadeh4, Nour Hamdan4, Hassan AbuKhalaf4, Mohamed Gharaibeh5, Hanadi Hamadallah6, Ala'abader7, Mohammad Atout4, Sae’ed Moh. Mar’I4, Tamer Alhamed4 Abstract 1 Department of Medicine, School of Medicine, The University of Jordan. Amman, Jordan. 2 Al Khalidi Hospital, Clinical Pharmacy, Amman, Jordan. 3 Department of Clinical Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan. 4 Department of Medicine. The Specialty Hospital. Amman, Jordan. 5 Department of Anesthesia, The Specialty Hospital. Amman, Jordan. 6 Jordan hospital, Department of Pharmacy. Amman, Jordan. 7 The Specialty hospital. Department of pharmacy. Amman, Jordan. Background: Vitamin D3 (1,25(OH)2cholecalciferol) as a treatment for Contact information: COVID 19 patients is being disputed, and a clear clinical benefit is not being confirmed. Methods: A retrospective evaluation for COVID-19 patients who were treated with various cumulative doses of vitamin D. Data was extracted from the COVID-19 database, it included patients admitted to three hospitals in Amman, Jordan. Characteristics of patients were tabulated and compared for all-cohort, and propensity score index (PSI) adjustment. The comparison was based on two vitamin D strata (≤ 149,000 i.u. and > 150,000 i.u.). Logistic regression analysis was utilized to predict recovery, the need for oxygen, and all-cause mortality for all-cohort, IPSW, and IPTW patients, based on vitamin D cumulative doses during their hospital stay. Jamal Wadi Al Ramahi, MD, FIDSA.  Results: 1131 all-cohort and 768 PSI-adjusted patients were recruited. Except for antibiotics and antivirals, all other characteristics were balanced (P = NS). There were 1017 patients on vitamin D, 847 received cumulative ≤ 149,000 i.u., and 170 patients received cumulative dose © Under License of Creative Commons Attribution 3.0 License This article is available at: 1 The International Arabic Journal of Antimicrobial Agents ISSN: 2174-9094 ≥ 150,000 i.u. (Range 1000 – 385000). It was demonstrated that the escalation of the cumulative doses of vitamin D did not contribute to the assessed outcomes; all-cohort patients (OR = 1.000, 95% C.I. 1.000 to 1.000), IPSW (OR = 1.000, 95% C.I. 1.000 to 1.000), and the IPTW (OR = 1.000, 95% C.I. 1.000 to 1.000). Conclusion: In our patients’ cohorts, we could not demonstrate a beneficial effect for vitamin D therapy in COVID-19 patients in recovery, the need for home oxygen, and all-cause mortality, by hospital discharge.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop